Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

Analyst Ratings

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (?)
Ratings Breakdown: 1 Hold Rating(s), 10 Buy Rating(s)
Consensus Rating:Buy (Score: 2.91)
Consensus Price Target: $117.82 (72.22% upside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Show:
DateFirmActionRatingPrice TargetActions
7/25/2016Needham & Company LLCReiterated RatingBuy$152.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016FBR & CoReiterated RatingOutperform$180.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/5/2016Cowen and CompanyReiterated RatingBuy$150.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$111.00 -> $81.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$107.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Deutsche Bank AGSet Price TargetBuy$155.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Canaccord GenuityReiterated RatingBuy$160.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Janney Montgomery ScottInitiated CoverageBuy$139.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015Barclays PLCInitiated CoverageOverweight$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.66)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414($0.60)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.56)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.54)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.14)($1.08)($1.11)
Q2 20164($1.32)($1.19)($1.26)
Q3 20164($1.35)($1.25)($1.30)
Q4 20164($1.41)($0.96)($1.26)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateHeadline
07/27/16 11:03 AMAlnylam Pharmaceuticals Inc.: Alnylam Announces New Positive Interim Phase 1 ...
07/26/16 08:30 PMGlobal RNA Based Therapeutics Market Analysis, Statistics, Industry Review and Forecasts to 2020
07/26/16 08:30 PMAlnylam Pharma (ALNY) Announces Positive Fitusiran Phase 1 Data as Hemophilia and Rare Bleeding Disorders Treatment
07/26/16 08:30 PMAlnylam Pharmaceuticals Inc.: Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress
07/26/16 11:58 AMAlnylam Pharmaceuticals Inc.: Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once ... - The Wall Street Transcript
07/26/16 11:58 AMMost Volatile Biotech Stocks- Alnylam Pharmaceuticals (NASDAQ:ALNY), Tobira Therapeutics (NASDAQ:TBRA) - Seneca Globe
07/26/16 11:58 AMSignificant Movements: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) , Rock Creek Pharmaceuticals, Inc. (PNK:RCPI) - Street Updates
07/25/16 02:58 PMBRIEF-Alnylam Pharma Announces New Positive Interim Phase 1 Study Results for Fitusiran - Reuters
07/25/16 02:58 PMAlnylam Pharmaceuticals Inc.: Alnylam to Report New Clinical Results with Fitusiran at the World Federation of ... - The Wall Street Transcript
07/25/16 02:58 PMAnalysts' Alert and Insider Trading Report: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Post Registrar
07/25/16 11:28 AMAlnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders - [at noodls] - 07.25.2016 - Fitusiran Achieves Median Estimated Annualized Bleeding Rate of Zero in Patients without Inhibitors - - In Initial Low Dose Cohort of Patients with Inhibitors, Fitusiran Achieves Antithrombin ...
07/25/16 07:13 AMAlnylam Pharmaceuticals : to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress
07/25/16 07:00 AMAlnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress - [Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that Alnylam and collaborators will present interim results from the ongoing Phase 1 clinical trial with fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B and rare bleeding disorders at the World Federation of Hemophilia 2016 World Congress being held July ...
07/23/16 02:24 PMStock Up Nicely This Week: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - TGP
07/22/16 07:27 PMAlnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Technicals at Critical Inflection Point - CML News
07/22/16 02:25 PMAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 08:00 PMTop 5 Hepatology stories of the week
07/21/16 02:26 PMHigh Expectations Remain For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - TGP
07/20/16 03:31 PMEarnings Focus and Crowd Sourced Sentiment Review for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - TGP
07/20/16 03:31 PMRtw Investments LLC Increased Alnylam Pharmaceuticals INC (NASDAQ:ALNY) by $18.83 Million as Shares Declined - Consumer Eagle
07/20/16 03:31 PMAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Fundamental Star Rating Report - CML News
07/18/16 02:29 PMShares of Alnylam Pharmaceuticals (ALNY) Rally 3.7% - Trade Calls
07/18/16 02:29 PMBiotech Stocks Worth a Closer Look: Incyte Corporation (NASDAQ:INCY), Alnylam Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar
07/17/16 02:24 PMAnalysts Are Expecting this Stock to Rise: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - TGP
07/16/16 10:50 AMAlnylam Pharmaceuticals Incorporated (NASDAQ:ALNY) Short Interest Increased By 2.96% - Consumer Eagle
07/15/16 01:01 PMAnalyst Target and Average Rating Watch: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Press Telegraph
07/14/16 07:54 PMA Reversal for Alnylam Pharmaceuticals, Inc. Is Not Near. The Formed Multiple Bottom Pattern - Consumer Eagle
07/14/16 02:27 PMEarnings Surprise in Focus: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Investor Newswire
07/14/16 02:27 PMBiotechnology Equities Technical Updates -- Merrimack Pharma, Alnylam Pharma, CytRx, and Progenics Pharma - PR Newswire (press release)
07/14/16 11:18 AMAlnylam announces phase 1/2 clinical trial of ALN-HBV RNA therapeutic
07/13/16 02:27 PMAnalysts Spotlight: CVS Health Corporation (NYSE:CVS) , Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Street Updates
07/13/16 02:27 PMAlnylam Pharmaceuticals Inc Realized Volatility Hits a Dropping Level - CML News
07/13/16 10:31 AMShares Losing Ground for the Month; Investor Alert on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Engelwood Daily
07/13/16 10:31 AMAlnylam Pharmaceuticals Incorporated (NASDAQ:ALNY) Shorted Shares Increased 2.96% After Market Selling - Consumer Eagle
07/13/16 10:05 AMALNY Reports Positive Results from Patisiran’s Open Label Extension Study -
07/12/16 08:08 AMALNY Adopts Reproducible and Modular Drug Development Platform -
07/12/16 07:23 AMAlnylam to Host Third Annual "RNAi Roundtable" Webcast Series - [at noodls] - 07.12.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announcedthat it plans to host its 3 Annual series of webcast 'RNAi ...
07/11/16 07:30 PMAnalysts and Technical Snapshot on Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) - Street Report
07/11/16 07:13 AMHit List News Buzzer- Alnylam Pharmaceuticals (NASDAQ:ALNY), Dominion Resources (NYSE:D), Chico's FAS (NYSE ... - Seneca Globe
07/11/16 07:13 AMStock Performance Rundown on: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Press Telegraph
07/11/16 07:13 AMStock Rating Watch and Earnings Insight for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Press Telegraph
07/08/16 02:27 PMCan Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Improve on the Earnings Front? - Engelwood Daily
07/08/16 02:27 PMCompany Stock Focus for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Which Way Will Shares Head? - Press Telegraph
07/08/16 10:28 AMAlnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
07/07/16 03:11 PMAlnylam Initiates Phase 1/2 Clinical Trial for ALN-HBV, an Investigational RNAi Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection - [at noodls] - 07.07.2016 - Company Expects to Report Initial Clinical Data in mid-2017 - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today ...
07/07/16 10:22 AMBetter Buy: Alnylam Pharmaceuticals, Inc. vs. Incyte - Motley Fool
07/06/16 07:15 AMAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 07:15 AMStock Tracking Down This Month; Investor Alert on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Engelwood Daily
07/06/16 07:15 AMBroker Outlook For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Fiscal Standard
07/05/16 02:25 PMWhy Alnylam Pharmaceuticals, Inc. Is Down 37.3% This Year - Motley Fool

Social

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALNY
  • CUSIP: 02043Q10
Key Metrics:
  • Previous Close: $68.41
  • 50 Day Moving Average: $61.18
  • 200 Day Moving Average: $63.67
  • P/E Ratio: N/A
  • P/E Growth: -0.29
  • Market Cap: $5.75B
  • Beta: 2.47
  • Current Year EPS Consensus Estimate: $-4.89 EPS
  • Next Year EPS Consensus Estimate: $-5.53 EPS
Additional Links:
Alnylam Pharmaceuticals (NASDAQ:ALNY) Chart for Thursday, July, 28, 2016